TY - JOUR
T1 - Effect of infectious diseases on outcome after heart transplant
AU - Van De Beek, Diederik
AU - Kremers, Walter K.
AU - Del Pozo, Jose L.
AU - Daly, Richard C.
AU - Edwards, Brooks S.
AU - McGregor, Christopher G.A.
AU - Patel, Robin
N1 - Funding Information:
Dr van de Beek is supported by personal grants from the Meerwaldt Foundation and the Netherlands Organization for Health Research and Development (ZonMw); NWO-Rubicon grant 2006 ( 019.2006.1.310.001 ).
PY - 2008/3
Y1 - 2008/3
N2 - OBJECTIVE: To determine how often cardiac allograft recipients develop infectious diseases and how the infections affect these patients. PATIENTS AND METHODS: We retrospectively studied 313 patients who underwent heart transplant at Mayo Clinic's site in Rochester, MN, from January 1, 1988, through June 30, 2006. RESULTS: In the early postoperative period (ie, period between heart transplant and discharge from the hospital), infectious diseases occurred in 70 (22%) of 313 patients but were not associated with 1-year mortality; the most commonly infected sites were the lungs (7%), bloodstream (6%), upper respiratory tract (5%), and urinary tract (4%). In the 18 years after transplant, the cumulative incidence of infectious diseases was 93%; the most common infectious complications were skin and soft tissue (63%), urinary tract (46%), cytomegalovirus (40%), lung (36%), upper respiratory tract (23%), and varicella zoster virus (15%) infections. After adjustment for baseline predictors, lung (hazard ratio [HR], 3.87; 95% confidence interval [CI], 2.49-6.02; P<.001) and central nervous system (HR, 4.48; 95% CI, 1.75-11.46; P=.002) infections were predictive of mortality. Serum creatinine levels (HR, 1.74; 95% CI, 1.07-2.81; P=.02) and sirolimus use (HR, 2.72; 95% CI, 1.00-7.36; P=.05) were predictive of lung infection. Death occurred during the study period in 95 (30%) of 313 patients, with a cumulative incidence of 71% at 18 years. The cause of death was infection in 17 (18%) of 95 patients. CONCLUSION: Early postoperative infectious complications are frequent in cardiac allograft recipients but are not associated with 1-year mortality. Lung and central nervous system infections are predictors of mortality.
AB - OBJECTIVE: To determine how often cardiac allograft recipients develop infectious diseases and how the infections affect these patients. PATIENTS AND METHODS: We retrospectively studied 313 patients who underwent heart transplant at Mayo Clinic's site in Rochester, MN, from January 1, 1988, through June 30, 2006. RESULTS: In the early postoperative period (ie, period between heart transplant and discharge from the hospital), infectious diseases occurred in 70 (22%) of 313 patients but were not associated with 1-year mortality; the most commonly infected sites were the lungs (7%), bloodstream (6%), upper respiratory tract (5%), and urinary tract (4%). In the 18 years after transplant, the cumulative incidence of infectious diseases was 93%; the most common infectious complications were skin and soft tissue (63%), urinary tract (46%), cytomegalovirus (40%), lung (36%), upper respiratory tract (23%), and varicella zoster virus (15%) infections. After adjustment for baseline predictors, lung (hazard ratio [HR], 3.87; 95% confidence interval [CI], 2.49-6.02; P<.001) and central nervous system (HR, 4.48; 95% CI, 1.75-11.46; P=.002) infections were predictive of mortality. Serum creatinine levels (HR, 1.74; 95% CI, 1.07-2.81; P=.02) and sirolimus use (HR, 2.72; 95% CI, 1.00-7.36; P=.05) were predictive of lung infection. Death occurred during the study period in 95 (30%) of 313 patients, with a cumulative incidence of 71% at 18 years. The cause of death was infection in 17 (18%) of 95 patients. CONCLUSION: Early postoperative infectious complications are frequent in cardiac allograft recipients but are not associated with 1-year mortality. Lung and central nervous system infections are predictors of mortality.
UR - http://www.scopus.com/inward/record.url?scp=41549105004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41549105004&partnerID=8YFLogxK
U2 - 10.4065/83.3.304
DO - 10.4065/83.3.304
M3 - Article
C2 - 18315996
AN - SCOPUS:41549105004
SN - 0025-6196
VL - 83
SP - 304
EP - 308
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 3
ER -